Target (TGT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Shares of Micron Technology (MU) traded at an intraday record Monday after Bank of America raised its price target, saying the chipmaker will benefit from the booming demand for artificial intelligence (AI) products.
NOT FOR DISSEMINATION IN THE UNITED STATES OF AMERICA OR TO US WIRE SERVICES TORONTO, ON / ACCESSWIRE / June 17, 2024 / EV NICKEL INC. (TSX-V:EVNI) ("EVNi" or the "Company") is please to provide an update on its 2024 Exploration Plan and the commencement of diamond drilling on the Langmuir #2, high priority nickel target (see Figure 1).
The chip maker was gaining early Monday as Susquehanna analyst Christopher Rolland became its most bullish advocate.
Target reportedly lost market share in several of its key product categories in the first quarter. The retailer's share shrank in food and household goods, clothing, electronics, homewares and furniture — categories that collectively account for 60% of its revenue, Reuters reported Friday (June 14), citing data from market research firm GlobalData.
In trading on Friday, shares of Target crossed below their 200 day moving average of $140.93, changing hands as low as $139.71 per share. Target shares are currently trading down about 3% on the day.
Target (TGT) increases its quarterly dividend to $1.12 per share, reflecting a 1.8% rise from the previous level and marking the company's 53rd consecutive year of annual dividend growth.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Target (TGT) have what it takes?
Ark Invest CEO and founder Cathie Wood may be best known for her 2018 price prediction on Tesla Inc TSLA shares. The price prediction was heavily scrutinized but came true years later and helped boost the profile of Wood and the price of many Ark Invest ETFs.
Agios Pharmaceuticals develops therapies for rare diseases with a focus on Pyruvate Kinase activators like Pyrukynd for PK deficiency. AGIO is advancing its pipeline with research on Mitapivat for thalassemia and sickle cell disease, positioning itself for potential FDA approvals in 2025 and 2026. A $905 million upfront payment from Royalty Pharma is contingent on FDA approval of Vorasidenib by August 2024.
Target Corp. TGT, -1.57% said Wednesday it's raising its quarterly dividend by 1.8% to $1.12 a share from $1.10 previously. The new dividend is payable Sept.
A group of activist investors plans to criticize major retailers Target and Dick's Sporting Goods over "woke" policies at the companies' respective shareholder meetings on Wednesday.